Loading clinical trials...

Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients | Clinical Trials | Clareo Health

ENROLLING_BY_INVITATION

Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

NCT03727399•Mabylon AG

View on ClinicalTrials.gov

Summary

The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens
•Male or female patients older than 18 years
•Written informed consent for providing blood and also to allow experimental manipulation

Exclusion Criteria

•Age \< 18 years
•Any corticosteroids within the last three days
•Oral corticosteroid therapy within the last ten days
•Parenteral depot corticosteroids within the last three months

Locations (1)

Immunologie Zentrum Zürich

Zurich, Canton of Zurich, Switzerland

Key Dates

Start Date

October 1, 2018

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2025

Last Updated

May 2, 2025

Enrollment

300

ESTIMATED participants

Conditions

Pollen Allergy

Interventions

blood withdrawal

OTHER

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT04502966

Allergic RhinoconjunctivitisGrass Pollen Allergy

View study

COMPLETEDNA

A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment

NCT05560698

Grass Pollen AllergyRhinoconjunctivitis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

Inclusion Criteria

Exclusion Criteria

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment

Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy

Phase II Study of Grass Pollen Allergy Vaccine BM32